{"id":2943,"date":"2018-10-26T05:30:00","date_gmt":"2018-10-26T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/"},"modified":"2018-10-26T05:30:00","modified_gmt":"2018-10-26T05:30:00","slug":"xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/","title":{"rendered":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018"},"content":{"rendered":"
GOD F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT DRIVEN AV VARM PERFUSION<\/strong><\/div>\n

TREDJE KVARTALET 2018 (JUL – SEP)<\/span><\/p>\n

\u2022 Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 27 procent och uppgick till 40,9 MSEK (32,3). \u00d6kningen motsvarar 18 procent i lokala valutor. Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under kvartalet med 27 procent och uppgick till 40,3 MSEK (31,6). \u00d6kningen motsvarar 18 procent i lokala valutor.
<\/span>\u2022 F\u00f6rs\u00e4ljning av varmperfusion* uppvisade en rekordtillv\u00e4xt \u00f6ver 60 procent f\u00f6r kvartalet. F\u00f6rs\u00e4ljning av varm perfusion stod f\u00f6r 40 procent (30) av f\u00f6rs\u00e4ljningen utan kapitalvaror.
<\/span>\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 5,2 MSEK (4,1) motsvarande en EBITDA-marginal om 13 procent. F\u00f6r j\u00e4mf\u00f6relsekvartalet 2017 uppgick EBITDA justerat f\u00f6r j\u00e4mf\u00f6relsest\u00f6rande poster till 4,4 MSEK motsvarande en EBITDA marginal om 14 procent.
<\/span>\u2022 R\u00f6relseresultatet uppgick till 0,7 MSEK (0,4), efter avskrivningar om 4,5 MSEK (3,7).
<\/span>\u2022 Nettoresultatet uppgick till 0,1 MSEK (-0,4), vilket gav ett resultat per aktie om 0,00 SEK (-0,01).
<\/span>\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 3,7 MSEK (7,6).
<\/span>\u2022 Perfadex Plus, en f\u00f6rb\u00e4ttring av Perfadex har lanserats i USA.
<\/span>\u2022 XVIVOs nya prototyp av hj\u00e4rtpreservationsmaskin har genomg\u00e5tt pre-kliniska f\u00f6rs\u00f6k med goda resultat.<\/span><\/p>\n

PERIODEN 2018 (JAN \u2013 SEP)<\/span><\/p>\n

\u2022 Total f\u00f6rs\u00e4ljning under perioden \u00f6kade med 21 procent och uppgick till 129,5 MSEK (106,8). \u00d6kningen motsvarar 19 procent i lokala valutor. Segment f\u00f6rs\u00e4ljning utan kapitalvaror \u00f6kade under perioden med 19 procent och uppgick till 120,4 MSEK (101,6). \u00d6kningen motsvarar 16 procent i lokala valutor.
<\/span>\u2022 F\u00f6rs\u00e4ljning av varm perfusion* stod f\u00f6r 40 procent (32) av f\u00f6rs\u00e4ljningen utan kapitalvaror.
<\/span>\u2022 R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 20,4 MSEK (13,4) motsvarande en EBITDA-marginal om 16 procent. F\u00f6r j\u00e4mf\u00f6relseperioden 2017 uppgick EBITDA justerat f\u00f6r j\u00e4mf\u00f6relsest\u00f6rande poster till 15,7 MSEK motsvarande en EBITDA marginal om 15 procent.
<\/span>\u2022 R\u00f6relseresultatet uppgick till 7,9 MSEK (2,4), efter avskrivningar om 12,6 MSEK (11,1).
<\/span>\u2022 Nettoresultatet uppgick till 7,8 MSEK (0,7), vilket gav ett resultat per aktie om 0,30 SEK (0,03).
<\/span>\u2022 Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten var 26,0 MSEK (14,3).
<\/span>\u2022 Nyemission till f\u00f6ljd av utnyttjande av teckningsoptioner gav ett tillskott om cirka 19 MSEK.
<\/span>\u2022 PMA-ans\u00f6kan f\u00f6r STEEN Solution\u2122 och XPS\u2122 har inl\u00e4mnats till FDA.
<\/span>\u2022 Perfadex Plus, en uppgraderad version av Perfadex, har lanserats i Europa och USA.
<\/span>\u2022 Analys av resultat fr\u00e5n PrimECC\u00ae<\/sup>-studien visade att produkten \u00e4r s\u00e4ker samt visade p\u00e5 positiva kliniska resultat.
<\/span>\u2022 United Therapeutics och XVIVO Perfusion har inlett samarbete och United Therapeutics avser att anv\u00e4nda XVIVO Perfusions produkter i deras tj\u00e4nst inom organutv\u00e4rdering.
<\/span>\u2022 Reimbursement-koder (s.k. CPT-koder) f\u00f6r hela EVLP-processen i USA har varit p\u00e5 plats sedan 1 januari 2018, vilket f\u00f6renklar ers\u00e4ttningsprocessen f\u00f6r sjukhus p\u00e5 den amerikanska marknaden
<\/span>\u2022 4 XPS\u2122 levererades under perioden januari-september 2018. Vid periodens utg\u00e5ng hade 47 kliniker tillg\u00e5ng till XPS\u2122 eller LS\u2122.<\/span><\/p>\n

TELEFONKONFERENS<\/span><\/p>\n

VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14.00 fredagen den 26 oktober 2018. Telefon: +46 (0)8 5664 2651, ange kod 83059919#<\/span><\/p>\n

G\u00f6teborg den 26 oktober 2018<\/span>
XVIVO Perfusion AB (publ)<\/span>
Magnus Nilsson, VD<\/span><\/p>\n

*STEEN Solution\u2122 samt produkter och tj\u00e4nster relaterade till anv\u00e4ndningen av XPS\u2122 och LS\u2122.<\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n

Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n

F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n

Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 7:30 den 26 oktober 2018.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GOD F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT DRIVEN AV VARM PERFUSION TREDJE KVARTALET 2018 (JUL – SEP) \u2022 Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 27…<\/p>\n","protected":false},"template":"","class_list":["post-2943","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3"],"acf":[],"yoast_head":"\nXVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"GOD F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT DRIVEN AV VARM PERFUSION TREDJE KVARTALET 2018 (JUL – SEP) \u2022 Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 27...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\\\/\",\"name\":\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2018-10-26T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO","og_description":"GOD F\u00d6RS\u00c4LJNINGSTILLV\u00c4XT DRIVEN AV VARM PERFUSION TREDJE KVARTALET 2018 (JUL – SEP) \u2022 Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 27...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/","name":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2018-10-26T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-delarsrapport-januari-september-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) del\u00e5rsrapport januari \u2013 september 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}